Anetumab ravtansine, an ADC of anti-MSLN antibody linked to maytansinoid DM4 drug, was tested in a phase I study in metastatic solid tumours, including pancreatic cancer (NCT01439152) [37]. The gene discussed is MSLN; the disease is familial pancreatic carcinoma.